We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the PDF to learn about:
- Three agents in late-stage development for immunoglobulin A nephropathy (IgAN), Fabry disease, and hepatitis D virus (HDV) treatment.
- Other significant treatments expected to reach the market in the next 12 months.
- An update on gene therapies and biosimilars in the pipeline.
Information presented is from various publicly available resources and for informational purposes only. This document does not provide information on confidential CarelonRx proprietary clinical programs or management strategies.
You may also be interested in:
Q1 2026 CarelonRx DrugInsights Update
Regulatory and Legislative Activity Update Q1 2026